Skip to main content
Top
Published in: Virology Journal 1/2020

01-12-2020 | Hepatitis B | Research

Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B

Authors: Liangdong Zhang, Zichao Wang

Published in: Virology Journal | Issue 1/2020

Login to get access

Abstract

Background

The present study aims to explore the functions of circular RNA hsa_circ_0004812 in chronic hepatitis B (CHB) and its underlying molecular mechanisms.

Methods

The expression of circular RNA (circRNA)_0004812 was examined using qRT-PCR and Western blot in blood and liver tissues from CHB patients and healthy volunteers. In the in vitro study, the expression levels of circular RNA hsa_circ_0004812, miR-1287-5p, interferon (IFN)-α, IFN-β were determined using qRT-PCR and Western blotting in HBV-infected hepatoma cells, respectively. Luciferase and biotin pull-down assays were used to investigate the interactions between miR-1287-5p and circ_0004812.

Results

Levels of circ_0004812 were upregulated in CHB patients and HBV-infected hepatoma cells. Knockdown of circ_0004812 increased the expression of IFN-α and IFN-β in HBV-infected Huh7 cells. MiR-1287-5p was identified as a target of circ_0004812 whose overexpression inhibited the expression of miR-1287-5p. Additionally, circ_0004812 promoted the expression of Follistatin-related protein (FSTL) 1 through inhibiting miR-1287-5p. Circ_0004812/miR-1287-5p/FSTL1 axis regulated HBV-induced immune suppression.

Conclusion

Circ_0004812 was identified as a potential target for CHB infection. Circ_0004812 promoted the expression of FSTL1 by inhibiting miR-1287-5p.
Literature
1.
go back to reference Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2018;26:33–42.CrossRefPubMed Tsai KN, Kuo CF, Ou JJ. Mechanisms of hepatitis B virus persistence. Trends Microbiol. 2018;26:33–42.CrossRefPubMed
2.
go back to reference Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615–25.CrossRefPubMed Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, Loglio A, Facchetti F, Lampertico P, Levrero M, Zoulim F. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019;70:615–25.CrossRefPubMed
3.
go back to reference Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313–24.CrossRefPubMed Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313–24.CrossRefPubMed
4.
go back to reference Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef Polaris Observatory C. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3:383–403.CrossRef
5.
go back to reference Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.PubMed Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99.PubMed
6.
go back to reference Thibault V. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2018;3:145–7.CrossRefPubMed Thibault V. Hepatitis B virus reactivation after direct-acting antivirals for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2018;3:145–7.CrossRefPubMed
7.
go back to reference Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol. 2018;11:519–24.CrossRefPubMed Ponziani FR, Miele L, Tortora A, Furnari M, Bodini G, Pompili M, Gasbarrini A, Giannini EG. Treatment of early stage chronic hepatitis C virus infection. Expert Rev Clin Pharmacol. 2018;11:519–24.CrossRefPubMed
8.
go back to reference Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K, Li H. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365:141–8.CrossRefPubMed Qu S, Yang X, Li X, Wang J, Gao Y, Shang R, Sun W, Dou K, Li H. Circular RNA: a new star of noncoding RNAs. Cancer Lett. 2015;365:141–8.CrossRefPubMed
9.
go back to reference Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–11.CrossRefPubMed Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17:205–11.CrossRefPubMed
11.
go back to reference Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869–81 e813.CrossRefPubMedPubMedCentral Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, et al. The landscape of circular RNA in Cancer. Cell. 2019;176:869–81 e813.CrossRefPubMedPubMedCentral
12.
go back to reference Peng L, Yuan XQ, Li GC. The emerging landscape of circular RNA ciRS-7 in cancer (review). Oncol Rep. 2015;33:2669–74.CrossRefPubMed Peng L, Yuan XQ, Li GC. The emerging landscape of circular RNA ciRS-7 in cancer (review). Oncol Rep. 2015;33:2669–74.CrossRefPubMed
13.
go back to reference Wang S, Cui S, Zhao W, Qian Z, Liu H, Chen Y, Lv F, Ding HG. Screening and bioinformatics analysis of circular RNA expression profiles in hepatitis B-related hepatocellular carcinoma. Cancer Biomark. 2018;22:631–40.CrossRefPubMed Wang S, Cui S, Zhao W, Qian Z, Liu H, Chen Y, Lv F, Ding HG. Screening and bioinformatics analysis of circular RNA expression profiles in hepatitis B-related hepatocellular carcinoma. Cancer Biomark. 2018;22:631–40.CrossRefPubMed
14.
go back to reference Yu J, Ding WB, Wang MC, Guo XG, Xu J, Xu QG, Yang Y, Sun SH, Liu JF, Qin LX, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. Int J Cancer. 2020;146:1754–63.CrossRefPubMed Yu J, Ding WB, Wang MC, Guo XG, Xu J, Xu QG, Yang Y, Sun SH, Liu JF, Qin LX, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. Int J Cancer. 2020;146:1754–63.CrossRefPubMed
15.
go back to reference Zhou TC, Li X, Chen LJ, Fan JH, Lai X, Tang Y, Zhang L, Wei J. Differential expression profile of hepatic circular RNA s in chronic hepatitis B. J Viral Hepat. 2018;25:1341–51.CrossRefPubMed Zhou TC, Li X, Chen LJ, Fan JH, Lai X, Tang Y, Zhang L, Wei J. Differential expression profile of hepatic circular RNA s in chronic hepatitis B. J Viral Hepat. 2018;25:1341–51.CrossRefPubMed
16.
go back to reference Yang H, Wang J, Fan JH, Zhang YQ, Zhao JX, Dai XJ, Liu Q, Shen YJ, Liu C, Sun WD, Sun Y. Ilexgenin a exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicol Appl Pharmacol. 2017;315:90–101.CrossRefPubMed Yang H, Wang J, Fan JH, Zhang YQ, Zhao JX, Dai XJ, Liu Q, Shen YJ, Liu C, Sun WD, Sun Y. Ilexgenin a exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth. Toxicol Appl Pharmacol. 2017;315:90–101.CrossRefPubMed
17.
go back to reference Zhao Y, Yu Y, Ye L. MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B. Infect Genet Evol. 2019;74:103919.CrossRefPubMed Zhao Y, Yu Y, Ye L. MiR-3613-3p impairs IFN-induced immune response by targeting CMPK1 in chronic hepatitis B. Infect Genet Evol. 2019;74:103919.CrossRefPubMed
18.
go back to reference Guo H, Qi RQ, Sheng J, Liu C, Ma H, Wang HX, Li JH, Gao XH, Wan YS, Chen HD. MiR-155, a potential serum marker of extramammary Paget's disease. BMC Cancer. 2018;18:1078.CrossRefPubMedPubMedCentral Guo H, Qi RQ, Sheng J, Liu C, Ma H, Wang HX, Li JH, Gao XH, Wan YS, Chen HD. MiR-155, a potential serum marker of extramammary Paget's disease. BMC Cancer. 2018;18:1078.CrossRefPubMedPubMedCentral
19.
go back to reference Yu J, Ding WB, Wang MC, Guo XG, Xu J, Xu QG, Yang Y, Sun SH, Liu JF, Qin LX, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: a large-scale, multicenter study. Int J Cancer. 2019;146:1754–63. Yu J, Ding WB, Wang MC, Guo XG, Xu J, Xu QG, Yang Y, Sun SH, Liu JF, Qin LX, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: a large-scale, multicenter study. Int J Cancer. 2019;146:1754–63.
20.
go back to reference Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology. 2004;40:727–37.CrossRefPubMed Wong DK, Yuen MF, Yuan H, Sum SS, Hui CK, Hall J, Lai CL. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology. 2004;40:727–37.CrossRefPubMed
21.
go back to reference Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, Zhuang H. Correlation of HBcrAg with intrahepatic hepatitis B virus Total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. J Clin Microbiol. 2019;57:e01303–18.PubMedPubMedCentral Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, Zhuang H. Correlation of HBcrAg with intrahepatic hepatitis B virus Total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. J Clin Microbiol. 2019;57:e01303–18.PubMedPubMedCentral
22.
go back to reference Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995–8.CrossRefPubMed Ozaras R, Tabak F, Tahan V, Ozturk R, Akin H, Mert A, Senturk H. Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment. Dig Dis Sci. 2008;53:2995–8.CrossRefPubMed
23.
go back to reference Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M. Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B. Taehan Kan Hakhoe Chi. 2003;9:284–92.PubMed Kim KH, Na IH, Cha JM, Cho YK, Park SY, Kim HP, Song CS, Heo J, Cho M. Serum ALT and HBV DNA levels in patients with HBeAg-negative chronic hepatitis B. Taehan Kan Hakhoe Chi. 2003;9:284–92.PubMed
24.
go back to reference Malmgaard L. Induction and regulation of IFNs during viral infections. J Interf Cytokine Res. 2004;24:439–54.CrossRef Malmgaard L. Induction and regulation of IFNs during viral infections. J Interf Cytokine Res. 2004;24:439–54.CrossRef
25.
go back to reference Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, et al. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Res. 2019;21:20.CrossRefPubMedPubMedCentral Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, et al. MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast Cancer Res. 2019;21:20.CrossRefPubMedPubMedCentral
26.
go back to reference Chaly Y, Hostager B, Smith S, Hirsch R. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res. 2014;59:266–72.CrossRefPubMed Chaly Y, Hostager B, Smith S, Hirsch R. Follistatin-like protein 1 and its role in inflammation and inflammatory diseases. Immunol Res. 2014;59:266–72.CrossRefPubMed
28.
go back to reference Seki M, Powers JC, Maruyama S, Zuriaga MA, Wu CL, Kurishima C, Kim L, Johnson J, Poidomani A, Wang T, et al. Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure. Circ Heart Fail. 2018;11:e004486.CrossRefPubMedPubMedCentral Seki M, Powers JC, Maruyama S, Zuriaga MA, Wu CL, Kurishima C, Kim L, Johnson J, Poidomani A, Wang T, et al. Acute and chronic increases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure. Circ Heart Fail. 2018;11:e004486.CrossRefPubMedPubMedCentral
Metadata
Title
Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B
Authors
Liangdong Zhang
Zichao Wang
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Hepatitis B
Published in
Virology Journal / Issue 1/2020
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/s12985-020-01314-0

Other articles of this Issue 1/2020

Virology Journal 1/2020 Go to the issue